1	Application of Rare	Variant Transmission-Disequilibrium Tests to Epileptic
2	F	Encephalopathy Trio Sequence Data
3		
4		
5	Running title: Epileptic end	cephalopathies and recessive genotypes
6		
7	Authors: Epi4K Consortiu	m, EuroEPINOMICS-RES Consortium, and Epilepsy Phenome
8	Genome Project	
9		
10	Corresponding author:	Epi4K Consortium
11		701 West 168th St., New York, NY 10032
12		Epi4K@columbia.edu
13		

14 **Funding Support:**

This work was supported by grants from the National Institute of Neurological Disorders 15 and Stroke (The Epilepsy Phenome/Genome Project NS053998; Epi4K NS077364, 16 17 NS077274, NS077303, and NS077276), The Andrew's Foundation, Finding a Cure for Epilepsy and Seizures, the Richard Thalheimer Philanthropic Fund, and the Eurocores 18 program EuroEPINOMICS-RES of the European Science Foundation. The project received 19 20 further support through grants from the Fund for Scientific Research Flanders (FWO); the 21 Academy of Finland (141549); the Folkhälsan Research Foundation; the program "Investissements d'avenir" ANR-10-IAIHU-06; the Federal Ministry for Education and 22 23 Research (IonNeurONet: 01GM1105), the German Research Foundation (DFG: HE5415/3-

1; Le1030/11-1; RO3396/2-1), the German Society for Epileptology (DGfE), the 24 Foundation noepilep.; the Swiss National Science Foundation (SNF: 32EP30 136042/1); 25 26 the Wellcome Trust (09805); intramural funds of the University of Kiel; the Popgen 2.0 network (P2N) through the German Ministry for Education and Research (01EY1103); the 27 28 European Union through Seventh Framework Programme (FP7) under the project DESIRE 29 (N602531). The project also received infrastructural support through the Institute of Clinical Molecular Biology in Kiel, supported in part by DFG Cluster of Excellence 30 "Inflammation at Interfaces" and "Future Ocean". The sponsors of the study had no role 31 32 in study design, data collection, data analysis, data interpretation, or writing of the report. 33 Orrin Devinsky, David B. Goldstein, Steve Petrou and Slavé Petrovski have interests in 34 companies related to epilepsy precision medicine.

36 Abstract

The classic epileptic encephalopathies, including Infantile Spasms (IS) and Lennox-Gastaut 37 Syndrome (LGS), are severe seizure disorders that usually arise sporadically. De novo 38 mutations in genes mainly encoding ion channel and synaptic proteins have been found to 39 40 account for over 15% of patients with IS or LGS. The contribution of autosomal recessive genetic variation, however, is less well understood. We implemented a rare variant 41 transmission-disequilibrium test (TDT) to search for autosomal recessive epileptic 42 encephalopathy genes in a cohort of 320 outbred patient-parent trios that were generally 43 pre-screened for rare metabolic disorders. In the current sample, our rare variant 44 transmission-disequilibrium test did not identify individual genes with significantly 45 46 distorted transmission over expectation after correcting for the multiple tests. While the rare variant transmission-disequilibrium test did not find evidence of a role for autosomal 47 48 recessive genes, our current sample is insufficiently powered to assess the overall role of 49 autosomal recessive genotypes in an outbred epileptic encephalopathy population.

50

51 Keywords: Epileptic encephalpathy; infantile spasms; transmission-disequilibrium test
52 (TDT); recessive genotypes

54 INTRODUCTION

Epileptic encephalopathies are severe and therapy-resistant epilepsies of childhood, which 55 frequently lead to developmental delay and multiple associated medical issues. Infantile 56 Spasms (IS) and Lennox-Gastaut Syndrome (LGS) represent two of the more common 57 58 broad subtypes of epileptic encephalopathies. Many novel genes for epileptic encephalopathies have been discovered in the last five years, fueled by the access to whole-59 60 exome sequencing. In particular, exome sequencing has highlighted the important role of de novo mutations with current estimates suggesting that over 15% of classical epileptic 61 encephalopathy cases are explained by a *de novo* mutation in an established epileptic 62 encephalopathy gene.^{1; 2} Up to a further 3% have been reported to be explained by likely 63 pathogenic *de novo* copy number variants (CNVs).³ 64

65 While the role of *de novo* genetic variation in epileptic encephalopathies is increasingly 66 understood, the role of recessive genetic variation, outside of recessive neurometabolic 67 disorders such as lysosomal disorders, amino acid or organic acid imbalances, congenital 68 disorders of glycosylation, and some mitochondrial diseases, remains unclear. In our 69 current study we systematically assessed autosomal recessive inheritance in 320 IS or LGS 70 patient-parent trios who did not have a likely disease-causing de novo mutation among one of the established dominant epileptic encephalopathy genes.^{1; 2} In general, the 320 cases 71 72 studied here had already been intensively studied for neurometabolic disorders using 73 biochemical assessments.

74

76 SUBJECTS and METHODS

77 Cohort

Three-hundred and twenty epileptic encephalopathy trios were recruited through multiple 78 international consortia, including 57 IS or LGS trios unpublished in our earlier studies.^{1; 2} 79 80 Patients did not have a clearly identified metabolic or genetic cause for their epilepsy based on clinically available testing, which varied across institutions. This collection of 320 trios 81 82 did not include: a) patients previously found to have a *de novo* mutation in an established dominant epileptic encephalopathy gene, and b) trios where exome sequencing was based 83 on a lymphoblastoid cell line (LCL) source for at least one of the three family members. 84 The overall cohort was not enriched for consanguineous parents. Only two parent pairs 85 86 showed an identity-by-descent (IBD) > 0.125, both < 0.15, which is approximately equivalent to 3rd degree relatives.⁴ 87

Among the 320 trios; two families reported multiple affected children. For one of these families both the proband and affected sibling were investigated through exome sequencing while for the second family only the proband and parents were studied. Sequencing methods used to generate the sequence data have been previously described.^{1; 2}

92

93 Transmission Disequilibrium Tests

For the transmission test we used two approaches that we have previously introduced.^{5; 6} First, we tested for an autosomal homozygous or compound heterozygous effect using coreTDT.⁶ In computing the test, we selected loss-of-function and missense single nucleotide substitution variants (SNVs) found at a global population minor allele frequency

below five percent (MAF<0.05). The loss-of-function variants were defined as stop gain,
stop lost, start lost and canonical splice acceptor and donor site variants. For the missense
variants we used our in-house Analysis Tool for Annotated Variants (ATAV) platform to
identify the possibly and probably damaging variants based on a maximum Polyphen-2
HumDiv and HumVar prediction score⁷ of greater than 0.4333. This test was applied to
each autosomal gene individually as well as collectively across a set of 99 autosomal
recessive neurometabolic genes published by van Karnebeek and colleagues.⁸

Second, we tested for a general effect of inherited autosomal variation by using a rare variant TDT that uses information from an independent collection of population controls (6503 EVS⁹ plus 1,303 IGM sequenced controls) to weight the contribution of variants to the final test statistic.⁵ In this analysis, qualifying variants were defined using the same PolyPhen-2 thresholds as above and were again required to have a global MAF less than 5%. Given that population stratification can impact the power of the test but not the type I error, we restricted this second analysis to trios with European ancestry (n=286 trios).

112

113 **RESULTS**

We assessed the role of inherited rare variation using the population control-weighted rarevariant TDT.⁵ This test was applied to each autosomal gene across 320 eligible trios. No gene reached exome-wide significance after correcting for the 17,816 consensus coding sequence (CCDS release 14) autosomal genes (adjusted $\alpha = 2.81 \times 10^{-6}$, Table 1). Though population stratification cannot affect the false positive rate of the test, it can affect the power.⁵ We also conducted an analysis that was restricted to the 286 trios of European
ancestry. Again, no gene reached the exome-wide significance level (Table 1).

We then tested for the presence of a recessive effect in each autosomal gene across the 320 trios. After quality control, only 3,472 autosomal genes were found to have at least one informative family, i.e., contain qualifying variants within the gene and that could, potentially, lead to homozygous or compound heterozygous offspring. None of these 3,472 genes achieved significance after correcting for the number of genes tested (adjusted $\alpha =$ 1.44 × 10⁻⁵). The 10 most significant genes are listed in Table 2.

To investigate whether there is any evidence of recessive neurometabolic involvement in this sample, we also applied the coreTDT to the 99 autosomal recessive neurometabolic genes,⁸ looking for an enrichment of homozygous or compound heterozygous offspring across the entire gene set. No enrichment was found (p = 0.51).

A power simulation was conducted to evaluate the types of effects that we could exclude 131 132 based on this analysis. In these simulations, we conditioned on the parental genotype 133 information contained in this IS/LGS population sample and characterized the distribution 134 of offspring genotypes given this information and the fact that the offspring is affected. This distribution is a function of the number of causal genes, for which the family is 135 136 informative, which is related to the density of causal genes within the actual gene set, and 137 the relative risk of the offspring developing disease given that they have two affected gene copies (Supplementary Methods). Offspring are randomly sampled from this distribution 138 and the resulting dataset is analyzed via coreTDT.⁶ Since only 54 families are informative 139 for at least one of the 99 autosomal recessive neurometabolic genes, and only 20 genes 140

have at least one informative family, our analyses are effectively restricted to these 54 families and 20 genes. We vary the proportion of informative genes that are actually disease causal and the relative risk and identify combinations of these parameters that attain at least 80% power (Figure 1). As can be seen, even when the compound heterozygous or homozygous qualifying variants are fully penetrant, the causal gene proportion must be larger than 40% to attain 80% power. When the proportion of causal genes is larger, e.g., 80%, we will have high power to detect an effect even with a relatively low relative risk.

Using established standards to identify pathogenic recessive genotypes^{10; 11}, one trio was found to have inherited two *SPATA5* pathogenic variants in a compound heterozygous manner.¹² The proband's phenotype is consistent with the *SPATA5* disease literature, and both pathogenic variants (p.Tyr559* and p.Arg84Gln) have previously been described as pathogenic among patients with *SPATA5* encephalopathy.¹²

153

154 **DISCUSSION**

A number of rare recessive disorders can present with an epileptic encephalopathy, 155 particularly neurometabolic disorders; the latter are generally identified by biochemical 156 analyses of blood, urine or CSF. We performed a global, hypothesis-free test to assess the 157 158 role of autosomal recessive genetic variation in 320 patients with classic epileptic 159 encephalopathies undiagnosed with standard clinical workups. Our sample of patient-parent 160 trios did not identify a genome-wide significant departure in the observed number of 161 offspring with recessive genotypes from that expected for any specific gene, or among 99 genes compiled for autosomal recessive neurometabolic disorders. 162

163 Many classical recessive metabolic disorders are routinely identified through biochemical screening prior to research study enrollment. Within our sample of 320 trios we did not find 164 any genetic neurometabolic disorders that were missed through the conventional 165 biochemical screening. From a clinical perspective, we emphasize that evaluation for these 166 167 treatable causes should continue to be pursued. We did, however, identify a single case among the 320 with a known pathogenic recessive genotype in SPATA5.¹² a recently 168 described gene for a recessive condition characterized by seizures, microcephaly, 169 170 intellectual disability, and hearing loss.

171 The role of various dominant epilepsy genes including ALG13, CDKL5, DNM1, GABRB3, SCN1A, SCN2A, and STXBP1, for epileptic encephalopathies was securely established 172 173 through exome sequencing of 356 trios and subsequent genome-wide assessments for excess de novo mutations identified in individual genes.^{1; 2} No single gene passes a 174 175 comparable threshold among the 320 trios studied here when assessing autosomal recessive genotypes. We demonstrate that the current sample of 320 trios is insufficiently powered to 176 appropriately estimate what overall contribution autosomal recessive epilepsy genes have 177 178 on the epileptic encephalopathies. Using a similar approach, a recent study on 4,125 179 patient-parent trios with various developmental disorders identified two novel autosomal recessive disease genes exceeding genome-wide significance.¹³ emphasizing the 180 181 importance of acquiring larger numbers to more confidently interpret the current lack of signal for very rare genetic epilepsies with recessive inheritance. Large-scale collaborative 182 183 initiatives like the Epilepsy Genetic Initiative (EGI) and the Epi25 effort will aid the efforts to analyze genomic data on this scale. 184

185 Acknowledgments

We are deeply grateful to the probands, their families, clinical research coordinators, and referring physicians for their participation and provision of phenotype data and DNA samples used in this study.

We thank the EPGP Administrative (C. Freyer, K. Fox, R. Fahlstrom, S. Cristofaro, and K. 189 190 McGovern), and Bioinformatics Core (G. Nesbitt, K. McKenna, and V. Mays), staff at 191 Coriell Institute – NINDS Genetics Repository, and members of the Institute for Genomic 192 Medicine, Columbia University (P. Cansler, J. Charoensri, B. Copeland, S. Kamalakaran, J. 193 Keebler, B. Krueger, C. Malone, C. Mebane, and M. Cook) for their dedication and commitment to this work. We also thank R. Stewart, K. Gwinn, R. Corriveau, B. Fureman 194 195 and V. Whittemore from the National Institute of Neurological Disorders and Stroke for their careful oversight and guidance of both EPGP and Epi4K. 196

197 We thank the following organizations for assistance in publicizing EPGP; enabling us to 198 recruit participants effectively: AED Pregnancy Registry, American Epilepsy Society, Association of Child Neurology Nurses, California School Nurses Organization, Child 199 Neurology Society, Citizens United for Research in Epilepsy, Dravet Syndrome 200 201 Foundation, Epilepsy Alliance of Orange County, Epilepsy Foundation, Epilepsy Therapy 202 Project, Finding a Cure for Epilepsy and Seizures, IDEA League, InfantileSpasms.com, 203 Lennox-Gastaut Syndrome Foundation, PatientsLikeMe, People Against Childhood 204 Epilepsy, PVNH Support & Awareness, and Seizures & Epilepsy Education.

205 We would like to acknowledge the following individuals or groups for the contributions of 206 control samples: D. Daskalakis; P. Lugar; J. Milner; T. Young and K. Whisenhunt; Z.

207 Farfel, D. Lancet, and E. Pras; W. Lowe; R. Gbadegesin and M. Winn; K. Schmader, S. 208 McDonald, H. K. White and M. Yanamadala; A. Holden; E. Behr; C. Moylan; A. M. Diehl 209 and M. Abdelmalek; S. Palmer; G. Nestadt; J Samuels; Y. Wang; M. Carrington; M. 210 Harms; T. Miller; A. Pestronk; R. Bedlack; R. Brown; N. Shneider; S. Gibson; J. Ravits; A. 211 Gilter; J. Glass; F. Baas; E. Simpson; and G. Rouleau; K. Welsh-Bomer, C. Hulette, J. 212 Burke; The ALS Sequencing Consortium; The Murdock Study Community Registry and 213 Biorepository; M. Connors, L. Morris and the CHAVI investigators; the Carol Woods and 214 Crosdaile Retirement Communities; and DUHS (Duke University Health System) 215 Nonalcoholic Fatty Liver Disease Research Database and Specimen Repository. The 216 collection of control samples and data was funded in part by: Biogen Idec.; The Duke 217 Chancellor's Discovery Program Research Fund 2014; Bill and Melinda Gates Foundation; 218 The Division of Intramural Research; B57 SAIC-Fredrick Inc M11-074; Bryan ADRC NIA 219 P30 AG028377; The Ellison Medical Foundation New Scholar award AG-NS-0441-08; 220 National Institute of Mental Health (K01MH098126, R01MH097993); National Institute of 221 Allergy and Infectious Diseases (1R56AI098588-01A1); and National Institute of Allergy 222 and Infectious Diseases Center (U19-AI067854, UM1-AI100645).

The authors would like to thank the NHLBI GO Exome Sequencing Project and its ongoing studies which produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010).

229 Conflict of Interest / Funding Support

230 This work was supported by grants from the National Institute of Neurological Disorders 231 and Stroke (The Epilepsy Phenome/Genome Project NS053998; Epi4K NS077364, 232 NS077274, NS077303, and NS077276), The Andrew's Foundation, Finding a Cure for 233 Epilepsy and Seizures, the Richard Thalheimer Philanthropic Fund, and the Eurocores program EuroEPINOMICS-RES of the European Science Foundation. The project received 234 further support through grants from the Fund for Scientific Research Flanders (FWO); the 235 236 Academy of Finland (141549); the Folkhälsan Research Foundation; the program 237 "Investissements d'avenir" ANR-10-IAIHU-06; the Federal Ministry for Education and Research (IonNeurONet: 01GM1105), the German Research Foundation (DFG: HE5415/3-238 239 1; Le1030/11-1; RO3396/2-1), the German Society for Epileptology (DGfE), the Foundation noepilep.; the Swiss National Science Foundation (SNF: 32EP30 136042/1); 240 241 the Wellcome Trust (09805); intramural funds of the University of Kiel; the Popgen 2.0 242 network (P2N) through the German Ministry for Education and Research (01EY1103); the European Union through Seventh Framework Programme (FP7) under the project DESIRE 243 244 (N602531). The project also received infrastructural support through the Institute of 245 Clinical Molecular Biology in Kiel, supported in part by DFG Cluster of Excellence "Inflammation at Interfaces" and "Future Ocean". The sponsors of the study had no role 246 247 in study design, data collection, data analysis, data interpretation, or writing of the report. Orrin Devinsky, David B. Goldstein, Steve Petrou and Slavé Petrovski have interests in 248 249 companies related to epilepsy precision medicine.


250 **References**

- Epi4K Consortium, Epilepsy Phenome/Genome Project (2013). *De novo* mutations in
 epileptic encephalopathies. *Nature* 501, 217-221.
- EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome Project, and Epi4K
 Consortium (2014). *De novo* mutations in synaptic transmission genes including
 DNM1 cause epileptic encephalopathies. *Am J Hum Genet* 95, 360-370.
- 3. Epilepsy Phenome/Genome Project, Epi4K Consortium (2015). Copy number variant
 analysis from exome data in 349 patients with epileptic encephalopathy. *Ann Neurol*78, 323-328.
- 4. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller,
- J., Sklar, P., de Bakker, P.I., Daly, M.J., et al. (2007). PLINK: a tool set for wholegenome association and population-based linkage analyses. *Am J Hum Genet* 81,
 559-575.
- 5. Jiang, Y., Satten, G.A., Han, Y., Epstein, M.P., Heinzen, E.L., Goldstein, D.B., and
 Allen, A.S. (2014). Utilizing population controls in rare-variant case-parent
 association tests. *Am J Hum Genet* 94, 845-853.
- 6. Jiang, Y., McCarthy, J.M., and Allen, A.S. (2015). Testing the effect of rare compoundheterozygous and recessive mutations in case--parent sequencing studies. *Genet Epidemiol* 39, 166-172.
- 7. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P.,
 Kondrashov, A.S., and Sunyaev, S.R. (2010). A method and server for predicting
 damaging missense mutations. *Nat Methods* 7, 248-249.

- 8. van Karnebeek, C.D., Shevell, M., Zschocke, J., Moeschler, J.B., and Stockler, S. (2014).
 The metabolic evaluation of the child with an intellectual developmental disorder:
 diagnostic algorithm for identification of treatable causes and new digital resource. *Mol Genet Metab* 111, 428-438.
- 276 9. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA
 277 (URL: http://evs.gs.washington.edu/EVS/).
- 278 10. Zhu, X., Petrovski, S., Xie, P., Ruzzo, E.K., Lu, Y.F., McSweeney, K.M., Ben-Zeev,
- B., Nissenkorn, A., Anikster, Y., Oz-Levi, D., et al. (2015). Whole-exome
 sequencing in undiagnosed genetic diseases: interpreting 119 trios. *Genet Med* 17,
 774-781.
- 11. Need, A.C., Shashi, V., Hitomi, Y., Schoch, K., Shianna, K.V., McDonald, M.T.,
 Meisler, M.H., and Goldstein, D.B. (2012). Clinical application of exome
 sequencing in undiagnosed genetic conditions. *J Med Genet* 49, 353-361.
- 12. Tanaka, A.J., Cho, M.T., Millan, F., Juusola, J., Retterer, K., Joshi, C., Niyazov, D.,
 Garnica, A., Gratz, E., Deardorff, M., et al. (2015). Mutations in *SPATA5* are
 associated with microcephaly, intellectual disability, seizures, and hearing loss. *Am J Hum Genet* 97, 457-464.
- 13. Akawi, N., McRae, J., Ansari, M., Balasubramanian, M., Blyth, M., Brady, A.F.,
 Clayton, S., Cole, T., Deshpande, C., Fitzgerald, T.W., et al. (2015). Discovery of
 four recessive developmental disorders using probabilistic genotype and phenotype
 matching among 4,125 families. *Nat Genet* 47, 1363-1369.
- 293
- 294

FIGURE LEGEND

- **Figure 1.** coreTDT power simulation conditional on the parental genotype of 54
- informative families and 20 informative genes in the compound heterozygous analysis.
- 298 Presents the combination of the relative risk and the proportion of disease causal genes
- among these 20 informative genes, under which the tests can achieve 80% power.



combination to achieve 80% power

Test	Gene	Number of SNVs [#]	Uncorrected p-value
	ABCA13	52	1.17E-05
	CENPO	4	0.00236
	DST	51	0.00297
Analysis of	IPPK	5	0.00198
rvTDT with	PCF11	10	0.00032
320 trios	SCAPER	5	0.00137
320 trios	SLC46A3	6	0.00185
	STEAP4	4	0.00291
	TRAF3IP1	7	0.00292
	ZNF878	7	0.00252
	ABCA13	52	0.00025
	SCAPER	5	0.00046
	ANKZF1	11	0.00079
Analysis of	DST	51	0.00123
rvTDT with	TRAF3IP1	7	0.00172
286 trios	STEAP4	4	0.00247
280 trios	SBSN	12	0.00295
	OR2B2	5	0.00298
	SAP130	8	0.00326
	SCARF1	11	0.00344

Table 1. Top 10 genes from the analysis of rvTDT with 320 and subsequently with the subset of

302 286 European ancestry trios.

[#]Representing the number of qualifying variants found in this gene across all families. P-value is based on the linear combination test with population controls. Adjusted α correcting for the number of genes is p < 2.81 × 10⁻⁶.

Gene	Number of SNVs [#]	Uncorrected p-value
PGM2L1	4	0.00195
CEP120	8	0.00391
CR1	25	0.00756
C140RF177	4	0.01288
CNTRL	24	0.01563
DACT1	8	0.01563
KATNB1	10	0.01563
SYNJ1	17	0.01563
ZNF677	11	0.01563
KIAA1614	15	0.01973

Table 2: Top 10 autosomal genes from the analysis of coreTDT with 320 trios

308 [#]Representing the number of qualifying variants found in this gene across all families. Adjusted

 α correcting for the number of genes is $p < 2.81 \times 10^{-6}$.

313 Supplementary Methods

314

315 Power Simulation

Let G_f, G_m, G_o be the number of gene copies harboring a qualifying mutation in the trio's father, 316 317 mother and offspring, respectively. We condition our power analysis on the observed parental genotype and study our ability to identify signal given a differing proportion of causal genes (out 318 of the total number of genes considered), γ , and differing relative risks, R, of being diseased 319 320 given two gene copies (of a causal disease gene) are affected versus less than two copies are affected. Since the analysis is conditional on the observed parental data, only a subset of genes 321 and families are informative. ⁶ Specifically, only 20 genes across 54 families can have 322 compound genotypes that lead to informative transmissions, i.e., $G_f = G_m = 1$, $G_f = 1$, $G_m = 2$ 323 or $G_f = 2, G_m = 1$. 46 families are informative for only one gene and eight families are 324 325 informative for two genes. In each of these eight families, the two genes are located on different 326 chromosomes, so we assume that the transmissions of each gene are independent.

327

Let $D_o = 1$ indicate the fact that the offspring is affected. Let *C* be an indicator of whether the gene whose transmission is being considered is among the set of disease causal genes or not. When a family is informative for two genes disease causal indicators are given for each gene by C_1 and C_2 . Note, we assume the disease risk for samples with multiple affected disease genes are the same with those with only one affected disease gene.

333

334 To simulate trios under the alternative, we first randomly select 20γ genes as disease causal and 335 then generate offspring as follows. 337 If the family is informative for only one gene, the distribution of both offspring's gene copies338 being affected is given by

$$\Pr(G_o = 2 | G_f = 1, G_m = 1, D_o = 1, C = 1) = \frac{R}{R+3}$$

$$\Pr(G_o = 2 | G_f + G_m = 3, D_o = 1, C = 1) = \frac{R}{R+1}$$

$$\Pr(G_o = 2 | G_f = 1, G_m = 1, D_o = 1, C = 0) = 0.75$$

$$\Pr(G_o = 2 | G_f + G_m = 3, D_o = 1, C = 0) = 0.5.$$

339

340 If the family is informative for two genes and no more than one of them are disease causal, the 341 compound genotype the two genes can be computed independently of one another using the 342 equation above. When both genes are disease causal, their transmissions are not independent 343 given the offspring is affected. In this case the compound genotypes of the offspring, for the two 344 genes, can be given by,

$$\Pr(G_{o1} = 2, G_{o2} = 2 | G_{f1} = G_{m1} = G_{f2} = G_{m2} = 1, D_o = 1, C_1 = C_2 = 1) = \frac{R}{7R + 9}$$
$$\Pr(G_{o1} = 2, G_{o2} \neq 2 | G_{f1} = G_{m1} = G_{f2} = G_{m2} = 1, D_o = 1, C_1 = C_2 = 1) = \frac{6R}{7R + 9}$$

345

$$\Pr(G_{o1} = 2, G_{o2} = 2 | G_{f1} = G_{m1} = 1, G_{f2} = 1, = G_{m2} = 2, D_o = 1, C_1 = C_2 = 1) = \frac{R}{5R + 3}$$

$$\Pr(G_{o1} = 2, G_{o2} \neq 2 | G_{f1} = G_{m1} = 1, G_{f2} = 1, = G_{m2} = 2, D_o = 1, C_1 = C_2 = 1) = \frac{R}{5R + 3}$$

$$\Pr(G_{o1} \neq 2, G_{o2} = 2 | G_{f1} = G_{m1} = 1, G_{f2} = 1, = G_{m2} = 2, D_o = 1, C_1 = C_2 = 1) = \frac{3R}{5R + 3}$$

where G_{o1}, G_{m1}, G_{f1} and G_{o2}, G_{m2}, G_{f2} denotes the trio's compound genotypes at the first and second gene, respectively. We apply coreTDT to each simulated dataset and for each combination of γ and R, we use 1000 replicates to estimate the power. The combination of γ and *R* which obtains 80% power are presented in Figure 1.

352 Consortium Membership

353 Epi4K

- Andrew S. Allen¹, Samuel F. Berkovic², Joshua Bridgers³, Patrick Cossette⁴, Dennis Dlugos⁵,
- 355 Michael P. Epstein⁶, Tracy Glauser⁸, David B. Goldstein³, Erin L. Heinzen³, Yu Jiang¹,
- 356 Michael R. Johnson⁹, Ruben Kuzniecky¹⁰, Daniel H. Lowenstein¹¹, Anthony G. Marson¹²,
- 357 Heather C. Mefford ¹³, Terence J. O'Brien ¹⁴, Ruth Ottman ¹⁵, Steven Petrou^{14,16,17}, Slavé
- Petrovski ^{2,3,14}, Annapurna Poduri ¹⁸, Zhong Ren ³, Ingrid E. Scheffer ¹⁹, Elliott Sherr ²⁰, Quanli
 Wang ³

360 EuroEPINOMICS-RES

Rudi Balling²¹, Nina Barisic²², Stéphanie Baulac²³, Hande Caglayan²⁴, Dana Craiu²⁵, Peter De 361 Jonghe²⁶, Christel Depienne²⁷, Renzo Guerrini²⁸, Ingo Helbig^{29, 30} Helle Hjalgrim³¹, Dorota 362 Hoffman-Zacharska³², Johanna Jähn²⁹, Karl Martin Klein^{33, 34}, Bobby Koeleman³⁵, Vladimir 363 Komarek³⁶, Roland Krause²¹, Eric Leguern²³, Anna-Elina Lehesjoki³⁷, Johannes R Lemke³⁸ 364 Holger Lerche³⁹, Tarja Linnankivi⁴⁰, Carla Marini²⁸, Patrick May²¹, Rikke S. Møller³¹, Hiltrud 365 Muhle²⁹, Deb Pal⁴¹ Aarno Palotie⁴², Felix Rosenow^{33, 34}, Kaja Selmer⁴³, Jose M Serratosa⁴⁴, 366 Sanjay Sisodiya⁴⁵, Ulrich Stephani²⁹, Katalin Sterbova³⁶, Pasquale Striano⁴⁶, Arvid Suls^{26, 47}, 367 Tiina Talvik⁴⁸, Sarah von Spiczak²⁹, Yvonne Weber³⁹, Sarah Weckhuysen²⁶, Federico Zara⁴⁹ 368

369 **EPGP**

- 370 Bassel Abou-Khalil ⁵⁰, Brian K. Alldredge ⁵¹, Dina Amrom ⁵², Eva Andermann ⁵³, Frederick
- 371 Andermann ⁵⁴, Jocelyn F. Bautista ⁵⁵, Samuel F. Berkovic ², Judith Bluvstein ¹⁰, Gregory D.
- 372 Cascino ⁵⁶, Damian Consalvo ⁵⁷, Patricia Crumrine ⁵⁸, Orrin Devinsky ⁵⁹, Dennis Dlugos ⁵,
- 373 Michael P. Epstein⁶, Miguel E. Fiol⁶⁰, Nathan B. Fountain⁶¹, Jacqueline French⁶², Daniel
- 374 Friedman⁶³, Tracy Glauser⁸, Kevin Haas⁶⁴, Sheryl R. Haut⁶⁵, Jean Hayward⁶⁶, Sucheta Joshi

375	⁶⁷ , Andres Kanner ⁶⁸ , Heidi E. Kirsch ⁶⁹ , Eric H. Kossoff ⁷⁰ , Rachel Kuperman ⁷¹ , Ruben
376	Kuzniecky ¹⁰ , Daniel H. Lowenstein ¹¹ , Shannon M. McGuire ⁷² , Paul V. Motika ⁷³ , Edward J.
377	Novotny ⁷⁴ , Ruth Ottman ¹⁵ , Juliann M. Paolicchi ⁷⁵ , Jack Parent ⁷⁶ , Kristen Park ⁷⁷ , Annapurna
378	Poduri ¹⁸ , Ingrid E. Scheffer ¹⁹ , Renée A. Shellhaas ⁷⁸ , Elliott Sherr ²⁰ , Joseph Sirven ⁷⁹ , Michael
379	C. Smith ⁸⁰ , Joseph Sullivan ¹¹ , Liu Lin Thio ⁸¹ , Anu Venkat ⁸² , Eileen P.G. Vining ⁸³ , Gretchen
380	K. Von Allmen ⁸⁴ , Judith L. Weisenberg ⁸⁵ , Peter Widdess-Walsh ⁸⁶ , Melodie R. Winawer ⁸⁷
381	
382	Author contributions
383	Sequence Analysis and Statistical Interpretation: Y.J. (lead analyst), A.S.A and D.B.G.
384	Bioinformatics processing: J.Br., E.L.H., Y.J., Sl.P., Z.R. and Q.W.
385	Clinical expert panel: I.H., H.C.M., A.P., and S.W.
386	Writing of manuscript: A.S.A., S.F.B., P.D.J., D.B.G., E.L.H., I.H., Y.J., D.H.L., and Sl.P.
387	
388	Epi4K Steering Committee: A.S.A, S.F.B., P.C., N.D., D.D., E.E.E., M.P.E., T.G., D.B.G.,
389	E.L.H., M.R.J., Ru.Ku., D.H.L., A.G.M., H.C.M., T.J.O., R.O., St.P, Sl.P., A.P., I.E.S., E.S.
390	EuroEPINOMICS-RES consortium leadership and study coordination: I.H., P.D.J., S.W.
391	EuroEPINOMICS Study design: A-E.L., A.S., B.K, H.L., I.H., P.G., P.D.J., S.W.
392	EPGP Study Design: B.K.A., O.D., D.D., M.P.E., Ru.Ku., D.H.L., R.O., E.S., M.R.W.
393	Epi4K Epileptic Encephalopathy Phenotyping: S.F.B., P.C., D.D., Ru.Ku., D.H.L., H.C.M.,
394	R.O., A.P., I.E.S., E.S.
	22

- **EuroEPINOMICS-RES Proband recruitment and phenotyping:** A-E.L., A.R., C.M., C.D.,
- 396 D.C., D.P., D.H., E.L., F.Z., F.Ros., H.C, H.H, H.M, H.L., I.H., J.J., J.L., J.S., K.Se., K.M.K.,
- 397 K.St., N.B., P.S., R.G., R.S.M., S.v.S., S.W., S.B., T.L. T.T., U.S., V.K., Y.W. EPGP
- **EPGP Proband Recruitment and Phenotyping:** B.A., E.A., F.A., D.A, J.F.B., S.F.B., G.D.C.,
- 399 D.Co., P.Cr., O.D., D.D., M.E.F., N.B.F., D.F., E.B.G., T.G., S.G., S.R.H., J.H., K.H, S.L.H.,
- 400 H.E.K., R.C.Kn., E.K., Ra.Ku., Ru.Ku, D.H.L., S.M.M., P.V.M., E.J.N., J.M.P., J.P., K.P., A.P.,
- 401 I.E.S., J.J.S., R.A.S., J.Si., L.S., M.S., L.L.T., A.V., E.P.G.V., G.K.V., J.W., P.W.
- 402 EPGP Phenotype Data Analysis: B.A., B.K.A., A.B., J.B., G.D.C., O.D., D.D., M.P.E., J.F.,
- 403 T.G., S.J., A.K., R.C.Kn., Ru.Ku., D.H.L., R.O., J.M.P., A.P., I.E.S., R.A.S., R.S., E.S., J.J.S.,
- 404 J.Su., P.W., M.R.W.
- 405

407 Affiliations

408 ^{1.} Department of Biostatistics and Bioinformatics, Duke Clinical Research Institute, Durham,

409 North Carolina 27710 USA.

- 410 ^{2.} Epilepsy Research Centre, Department of Medicine, University of Melbourne (Austin Health),
- 411 Heidelberg, Victoria 3084, Australia.
- ^{3.} Institute for Genomic Medicine, Columbia University Medical Center, New York, New York
 10032, USA.
- 414 ^{4.} Department of Neurosciences and CHUM Research Center, Université de Montréal, CHUM-
- 415 Hôpital Notre-Dam Montréal, Quebec H2L 4M1e, Canada.
- 416 ^{5.} Department of Neurology and Pediatrics, The Children's Hospital of Philadelphia, Perelman
- 417 School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104 USA.
- 418^{6.} Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia
- 419 30322, USA.
- 420^{7.} Howard Hughes Medical Institute, Department of Genome Sciences, University of Washington
- 421 School of Medicine, Seattle, Washington 98195 USA.
- ^{8.} Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229
 USA.
- 424 ^{9.} Centre for Clinical Translation Division of Brain Sciences, Imperial College London, London,
- 425 SW7 2AZ UK.
- 426 ^{10.} NYU School of Medicine, New York University, New York, New York 10016 USA.
- ^{11.} Department of Neurology, University of California, San Francisco, San Francisco, California
 94143 USA.

429	^{12.} Department of Molecular and Clinical Pharmacology, University of Liverpool, Clinical
430	Sciences Centre, Lower Lane, Liverpool, L9 7LJ, United Kingdom.
431	^{13.} Department of Pediatrics, Division of Genetic Medicine, University of Washington, Seattle,
432	Washington 98115 USA.

433 ^{14.} Departments of Medicine and Neurology, The Royal Melbourne Hospital, Parkville, Victoria,

434 3146 Australia.

435 ^{15.} Departments of Epidemiology and Neurology, and the G.H. Sergievsky Center, Columbia

436 University; and Division of Epidemiology, New York State Psychiatric Institute, New York,

437 New York 10032 USA.

^{16.} Florey Institute for Neuroscience and Mental Health. The University of Melbourne, VIC 3010,
Australia.

440 ^{17.} Centre for Neural Engineering. The University of Melbourne, VIC 3010, Australia.

441 ^{18.} Division of Epilepsy and Clinical Neurophysiology, Department of Neurology Boston

442 Children's Hospital, Boston, Massachusetts 02115 USA.

443 ^{19.} Epilepsy Research Centre, Department of Medicine, University of Melbourne (Austin Health),

444 Heidelberg, Victoria 3084, Australia, Florey Institute and Department of Pediatrics, Royal

445 Children' s Hospital, University of Melbourne, Victoria 3052, Australia.

446 ^{20.} Departments of Neurology, Pediatrics and Institute of Human Genetics, University of

447 California, San Francisco, San Francisco, California 94158 USA.

448 ^{21.} Luxembourg Centre for Systems Biomedicine, University of Luxembourg, L-4362 Esch-sur-

449 Alzette, Luxembourg

450 ²² Department of Paediatrics, University of Zagreb, Medical School, University Hospital Centre

451 Zagreb, 10000 Zagreb, Croatia

452	^{23.} Sorbonne Universités, UPMC Univ Paris 06, UM 75, F-75013 Paris, France; INSERM,
453	U1127, F-75013 Paris, France; CNRS, UMR 7225, F-75013 Paris, France ; ICM, F-75013 Paris,
454	France; Department of genetic and cytogenetic, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris,
455	France
456	²⁴ Department of Molecular Biology and Genetics, Bogazici University, 34342 Istanbul, Turkey
457	²⁵ Pediatric Neurology Clinic II, Department of Neurology, Pediatric Neurology, Psychiatry,
458	Neurosurgery, "Carol Davila" University of Medicine, Bucharest, Sector 4, Romania; Pediatric
459	Neurology Clinic, "Professor Doctor Alexandru Obregia" Clinical Hospital, Sector 4, Bucharest,
460	Romania
461	²⁶ Neurogenetics group, Department of Molecular Genetics, VIB, 2610 Antwerp, Belgium;
462	Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, 2610 Antwerp,
463	Belgium
464	²⁷ Département de Médicine translationnelle et Neurogénétique, IGBMC, CNRS UMR
465	7104/INSERM U964/Université de Strasbourg, 67400 Illkirch, France ; Laboratoire de
466	cytogénétique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
467	²⁸ Pediatric Neurology Unit and Laboratories, Children's Hospital A. Meyer – University of
468	Florence, 50132 Florence, Italy
469	²⁹ Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Christian-
470	Albrechts University, 24105 Kiel, Germany
471	³⁰ Division of Neurology, The Children's Hospital of Philadephia, 3401 Civic Center Blvd.,
472	Philadelphia, PA 19104-4399, USA
473	³¹ Danish Epilepsy Centre, Dianalund, Denmark; Institute for Regional Health research,
474	University of Southern Denmark, Odense, Denmark

- 475 ³² Department of Medical Genetics, Institute of Mother and Child, 01211 Warsaw, Poland
- 476 ³³ Epilepsy Center Rhine-Main, Center of Neurology and Neurosurgery, Goethe-University
- 477 Frankfurt, Schleusenweg 2-16, Haus 95, 60528 Frankfurt a.M.
- 478 ³⁴ Epilepsy Center Hessen, Philipps-University Marburg, Marburg, Germany
- 479 ³⁵ Department of Medical Genetics, University Medical Center, Utrecht, The Netherlands
- 480 ³⁶ Department of Child Neurology, Second Medical Faculty and University Hospital Motol, 150
- 481 06 Praha, Czech Republic
- 482 ³⁷ Folkhälsan Institute of Genetics; Research Programs Unit, Molecular Neurology and
- 483 Neuroscience Center, University of Helsinki, 00290 Helsinki, Finland
- 484 ³⁸ Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany
- 485 ³⁹ Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research,
- 486 University of Tübingen, 72076 Tübingen, Germany
- 487 ⁴⁰ Children's Hospital, Pediatric Neurology, University of Helsinki and Helsinki University
- 488 Central Hospital, FIN-00029 HUS, Helsinki, Finland
- 489 ⁴¹ Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London,
- 490 UK
- 491 ⁴² Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire
- 492 CB10 1SA, United Kingdom; Institute for Molecular Medicine Finland (FIMM), University of
- 493 Helsinki, 00290 Helsinki, Finland; Program in Medical and Population Genetics and Genetic
- 494 Analysis Platform, The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
- ⁴³ Department of Medical Genetics, Oslo University Hospital, Oslo, Norway

- 496 ⁴⁴ Epilepsy Unit, Department of Neurology, Institute of Medical Research at Fundación Jiménez
- 497 Díaz University Hospital and Centro de Investigación Biomédica en Red en Enfermedades Raras

498 (CIBERER) Unit 744, Madrid, Spain

- 499 ⁴⁵ Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK;
- 500 Epilepsy Society, Buckinghamshire, UK
- ⁴⁶ Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences,
- 502 Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genova and
- 503 Gaslini Institute, 16147 Genova, Italy
- ⁴⁷ GENOMED, Center of Medical Genetics, University of Antwerp & Antwerp University
- 505 Hospital, Antwerp, Belgium.
- ⁴⁸ Department of Pediatrics, University of Tartu, 51014 Tartu, Estonia; Department of Neurology
- and Neurorehabilitation, Children's Clinic, Tartu University Hospital, 50406 Tartu, Estonia
- ⁴⁹ Laboratory of Neurogenetics, Pediatric Neurology and Muscular Diseases Unit, Department of
- 509 Neurosciences, University of Genova and Gaslini Institute, 16147 Genova, Italy
- ^{50.} Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee 37232
- 511 USA.
- ^{51.} Department of Clinical Pharmacy, UCSF School of Pharmacy, Department of Neurology,
- 513 UCSF School of Medicine 94143 USA.
- ^{52.} Neurogenetics Unit, Montreal Neurological Hospital and Institute; Departments of Neurology
- 515 & Neurosurgery, McGill University, Montreal QC H3A 2B4 Canada
- ^{53.} Neurogenetics Unit and Epilepsy Research Group, Montreal Neurological Hospital and
- 517 Institute; Departments of Neurology & Neurosurgery and Human Genetics, McGill University,
- 518 Montreal QC H3A 2B4 Canada

- ^{54.} Epilepsy Research Group, Montreal Neurological Hospital and Institute; Departments of 519
- Neurology & Neurosurgery and Pediatrics, McGill University, Montreal OC H3A 2B4 Canada 520
- ^{55.} Department of Neurology, Cleveland Clinic Lerner College of Medicine & Epilepsy Center of 521
- 522 the Cleveland Clinic Neurological Institute, Cleveland, Ohio 44195 USA.
- ^{56.} Divison of Epilepsy, Mayo Clinic, Rochester, Minnesota 55905 USA. 523
- ^{57.} Epilepsy Center, Neurology Division, Ramos Mejía Hospital, Buenos Aires, 1221, Argentina. 524
- ^{58.} Medical Epilepsy Program & EEG & Child Neurology, Children's Hospital of Pittsburgh of 525
- UPMC, Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15224 526
- 527 USA.
- ^{59.} NYU and Saint Barnabas Epilepsy Centers, NYU School of Medicine, New York, New York 528 529 10016 USA.
- ^{60.} Department of Neurology, Epilepsy Care Center, University of Minnesota Medical School, 530
- 531 Minneapolis, Minnesota 55414 USA.
- ^{61.} FE Dreifuss Comprehensive Epilepsy Program, University of Virginia, Charlottesville, 532
- Virginia 22908 USA. 533
- ^{62.} NYU Comprehensive Epilepsy Center, New York, New York 10016 USA. 534
- ^{63.} Department of Neurology, NYU School of Medicine, New York, New York, 10016 USA. 535
- ^{64.} Vanderbilt University Medical Center, Nashville, Tennessee 37232 USA. 536
- ^{65.} Comprehensive Epilepsy Center, Montefiore Medical Center, Bronx, New York 10467 USA. 537
- ^{66.} The Kaiser Permanente Group, Oakland, California 94618 USA. 538
- ^{67.} Pediatrics & Communicable Diseases, University of Michigan, Ann Arbor, Michigan 48109 539 540 USA.

- ^{68.} Comprehensive Epilepsy Center, Department of Neurology, Miller School of Medicine,
- 542 University of Miami, Miami USA.
- ^{69.} Departments of Neurology and Radiology, University of California, San Francisco, California
 94143 USA.
- ^{70.} Neurology and Pediatrics, Child Neurology, Pediatric Neurology Residency Program, Johns
- 546 Hopkins Hospital, Baltimore, Maryland 21287 USA.
- ^{71.} Epilepsy Program, Children's Hospital & Research Center Oakland, Oakland, California
 94609 USA.
- 549 ^{72.} Clinical Neurology, Children's Hospital Epilepsy Center of New Orleans, New Orleans,
- 550 Louisiana 70118 USA.
- ^{73.} Comprehensive Epilepsy Center, Oregon Health and Science University, Portland, Oregon
 97239 USA.
- ^{74.} Departments of Neurology and Pediatrics, University of Washington School of Medicine,
- 554 Seattle Children's Hospital, Seattle, Washington 98105 USA.
- ^{75.} Weill Cornell Medical Center, New York, New York 10065 USA.
- ^{76.} Department of Neurology and Neuroscience Graduate Program, University of Michigan
- 557 Medical Center, Ann Arbor, MI 49108 and Ann Arbor Veterans Administration Healthcare
- 558 System, Ann Arbor, Michigan 48105 USA.
- ^{77.} University of Colorado School of Medicine, Aurora, Colorado 80045, U.S.A.; Division of
- 560 Neurology, Department of Pediatrics, Children's Hospital Colorado, Aurora, Colorado 80045
- 561 USA.
- ^{78.} University of Michigan, Pediatric Neurology, Ann Arbor, Michigan 48109 USA.
- ^{79.} Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259 USA.

^{80.} Department of Neurological Sciences, Rush Epilepsy Center, Rush University Medical

565 Center, Chicago, Illinois 60612 USA.

- ^{81.} Department of Neurology, Washington University School of Medicine, St. Louis, Missouri
 63110.
- 568 ^{82.} Department of Pediatrics, Saint Peter's University Hospital, New Brunswick, New Jersey,

569 08901

- ^{83.} Department of Neurology, Johns Hopkins Hospital, Baltimore, Maryland 21287 USA.
- 571 ^{84.} Division of Child & Adolescent Neurology, Departments of Pediatrics , University of Texas
- 572 Medical School, Houston, Texas 77030 USA.
- 573 ^{85.} Department of Neurology, Division of Pediatric Neurology, Washington University School of
- 574 Medicine, St. Louis, Missouri 63110 USA.
- ^{86.} Department of Neurology, Beaumont Hospital and Royal College of Surgeons, Dublin 9
- 576 Ireland.
- ^{87.} Department of Neurology and the G.H. Sergievsky Center, Columbia University, New York,
- 578 New York, 10032 USA.